Lingkang Pharmaceutical disclosed its earnings forecast, expecting to achieve a net profit attributable to the parent company of 23 million yuan in the first half of 2026, compared with a loss of 35.7337 million yuan in the same period last year, turning around from loss to profit year-on-year. The company expects operating revenue of 250 million yuan and a non-recurring net profit of 20 million yuan for the same period, compared with a non-recurring net loss of 45.5449 million yuan in the same period last year. The company stated that the improvement in performance was mainly due to increased promotion of varieties won in centralized procurement, leveraging channel advantages to expand the market for non-centralized procurement varieties, and deepening pharmaceutical distribution and agency business.
Lionco Pharm Grp Co LtdCompany expects net profit of 23 million yuan in H1 2026, turning around from loss year-on-year.